These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34357702)

  • 1. Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report.
    Sakai S; Morimoto Y; Matsuzaka Y; Nakano T; Kanegae S; Imamura A; Ozawa H
    Neuropsychopharmacol Rep; 2021 Sep; 41(3):440-443. PubMed ID: 34357702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study.
    Ohi K; Takai K; Kuramitsu A; Sugiyama S; Shioiri T
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 113():110470. PubMed ID: 34740708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
    Iwata N; Ishigooka J; Naoi I; Matsumoto M; Kanamori Y; Nakamura H; Higuchi T
    CNS Drugs; 2020 Jan; 34(1):103-116. PubMed ID: 31883082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
    Nishibe H; Tateno A; Sakayori T; Yamamoto M; Kim W; Kakuyama H; Okubo Y
    Int J Neuropsychopharmacol; 2021 Feb; 24(2):108-117. PubMed ID: 32936897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D
    Kitamura A; Takagaki T; Nemoto D; Tomita Y; Nishibe H; Kakuyama H
    J Clin Pharmacol; 2021 Aug; 61(8):1069-1080. PubMed ID: 33599975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.
    Iwata N; Ishigooka J; Kim WH; Yoon BH; Lin SK; Sulaiman AH; Cosca R; Wang L; Suchkov Y; Agarkov A; Watabe K; Matsui T; Sato T; Inoue Y; Higuchi T; Correll CU; Kane JM
    Schizophr Res; 2020 Jan; 215():408-415. PubMed ID: 31471246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D2 Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch.
    Tomita Y; Takagaki T; Kitamura A; Wada E; Nishibe H; Tateno A; Okubo Y
    J Clin Psychopharmacol; 2022 May-Jun 01; 42(3):260-269. PubMed ID: 35384896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe behavioral and psychological symptoms of dementia successfully treated at home with a blonanserin transdermal patch: A case report.
    Yamaguchi J; Sadahiro R; Hirayama T; Wada S; Nakahara R; Matsuoka H
    Neuropsychopharmacol Rep; 2024 Jun; 44(2):474-478. PubMed ID: 38558544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.
    Wietholter JP; Sizemore J; Piechowski K
    Am J Health Syst Pharm; 2020 Sep; 77(18):1477-1481. PubMed ID: 32761113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch.
    Hagikura M; Inada T
    Neuropsychopharmacol Rep; 2023 Mar; 43(1):150-153. PubMed ID: 36651841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of blonanserin transdermal patch on terminal delirium in patients with respiratory diseases.
    Ando K; Suzuki A; Yoshida H
    Respir Investig; 2023 Mar; 61(2):240-246. PubMed ID: 36791594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
    Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
    Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia.
    Kishi T; Nakamura H; Matsuura A; Iwata N
    Schizophr Res; 2022 Feb; 240():231-232. PubMed ID: 35091305
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
    Kawabe K; Horiuchi F; Ueno S
    Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal Delivery of Antipsychotics: Rationale and Current Status.
    Abruzzo A; Cerchiara T; Luppi B; Bigucci F
    CNS Drugs; 2019 Sep; 33(9):849-865. PubMed ID: 31493244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year follow-up study of psychotic patients treated with blonanserin: a case series.
    Takahashi S; Suzuki M; Uchiyama M
    Asia Pac Psychiatry; 2013 Sep; 5(3):164-7. PubMed ID: 23857800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
    Lanning RK; Zai CC; Müller DJ
    Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Management of Terminal Delirium With Transdermal Blonanserin Patch in a Terminally Ill Cancer Patient.
    Nishiofuku H; Mori M; Yokomichi N; Sakuma Y; Sugiyama K; Takashina Y; Miyagi A; Ishizuka M; Imai K; Morita T
    J Palliat Med; 2024 Feb; ():. PubMed ID: 38335445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Blonanserin Transdermal Patch in Home Treatment of Schizophrenia: A Case Study.
    Ogawa T; Tachikawa H; Shiratori Y; Sodeyama N; Taguchi T; Hori T; Arai T
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):603-605. PubMed ID: 34433201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.